FSD Pharma (FSDDF) Stock Price, News & Analysis

Company Overview

FSD Pharma Inc. is a Canadian biotechnology company focused on developing therapies for complex medical conditions, including neurodegenerative, inflammatory and psychiatric disorders. The company’s work centers on novel small-molecule and cannabinoid- or psychedelic-related compounds intended to address areas of unmet medical need.

FSD Pharma has historically advanced FSD-201, an ultramicronized formulation of palmitoylethanolamide, as a potential treatment for inflammatory conditions. The company has also pursued a research and development pipeline through its Lucid Psycheceuticals business, including Lucid-21-302, an investigational compound being studied for potential use in major depressive disorder and other central nervous system conditions.

Based in Toronto, Ontario, FSD Pharma conducts its activities primarily through pharmaceutical research, preclinical development and clinical-stage programs rather than through the sale of established commercial products. Its development efforts are oriented toward North American and international regulatory and clinical markets. The company’s programs and corporate strategy have evolved over time from an earlier emphasis on cannabinoid-based and anti-inflammatory therapies toward a broader focus on neuropsychiatric and neurodegenerative treatments.

Key Stats

• Today's Range: $2.80 to $2.97
• 50-Day Range: $2.82 to $3.96
• 52-Week Range: $3.43 to $68.66
• Volume: 84,862 shs
• Average Volume: 11,100 shs
• Market Capitalization: $21.91 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:FSDDF
• Previous Symbol: OTCMKTS:FSDDF
• CIK: N/A
• Web: www.quantumbiopharma.com
• Phone: (416) 854-8884
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.81
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 312.95
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,580,000
• Free Float: N/A
• Market Cap: $21.91 million
• Optionable: Not Optionable
• Beta: N/A